Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 6/20 | 0.34 |
| ▸ | HTR7 | P34969 | 6/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.32 |
| ▸ | AXL | P30530 | 3/20 | 0.32 |
| ▸ | MERTK | Q12866 | 3/20 | 0.32 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | HTR6 | P50406 | 1/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.31 |
| ▸ | PCK1 | P35558 | 1/20 | 0.30 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26806535 | 0.89 | TSHR (0.35) | HTR1AHTR7TSHRSMN1; SMN2BRD4 | |
| SCHEMBL26806532 | 0.88 | TSHR (0.34) | HTR1AHTR7TSHRSMN1; SMN2PIK3CD | |
| SCHEMBL26806537 | 0.86 | CDK1 (0.38) | HTR1AHTR7TSHRSMN1; SMN2PIK3CD | |
| SCHEMBL26806521 | 0.85 | TSHR (0.35) | HTR1AHTR7TSHRSMN1; SMN2BRD4 | |
| SCHEMBL26806527 | 0.84 | RORC (0.40) | HTR1AHTR7TSHRSMN1; SMN2PIK3CD | |
| SCHEMBL26806536 | 0.83 | HTR1A (0.35) | HTR1AHTR7TSHRSMN1; SMN2BRD4 | |
| SCHEMBL26809034 | 0.83 | MAP4K1 (0.31) | HTR1AHTR7JAK1NLRP3 | |
| SCHEMBL26806559 | 0.82 | IRAK4 (0.37) | HTR1AHTR7TSHRSMN1; SMN2BRD4 | |
| SCHEMBL26806544 | 0.81 | JAK1 (0.41) | HTR1AHTR7TSHRSMN1; SMN2PIK3CD | |
| SCHEMBL24309400 | 0.81 | TSHR (0.36) | HTR1AHTR7TSHRSMN1; SMN2BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS, SAN DIEGO | 2023-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230373935-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1G, SCNN1B | HTR1A 4018/4885HTR7 3833/4885TSHR 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.